Global Eye Health 2026: Tackling Glaucoma Disparities

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/global-eye-health-2026-tackling-glaucoma-disparitiesTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Global Eye Health 2026: Tackling Glaucoma Disparities Evidence reviewed through June 30, 2026 Glaucoma is often called a “silent thief of sight” because it can damage the optic nerve for years before a person notices a problem. Once vision is lost, it usually cannot be restored. However, early detection, pressure-lowering treatment, laser therapy, and surgery can often slow or stop further damage. The global glaucoma challenge is therefore not simply a lack of effective treatments. It is a problem of late detection, unequal access, medicine cost, weak referral systems, limited surgical capacity, and difficulty maintaining lifelong care. These problems are most severe in low-resource settings, rural communities, and groups facing financial or gender-related barriers. The global glaucoma burden in 2026 There is no single real-time worldwide glaucoma census. Different studies measure different outcomes: Total glaucoma disease includes people with early disease who may have no symptoms. Glaucoma-related blindness counts people whose glaucoma has caused profound vision loss. Disability-adjusted life years measure the combined effect of disability and premature loss of healthy life. These measures should not be treated as interchangeable. For the full table, please open this article on visualfieldtest.com. The long-standing global projection of 76 million people with glaucoma in 2020 and 111.8 million by 2040 comes from a systematic review of population eye studies. The 2024 global analysis of glaucoma-related vision loss estimated 3.61 million people were blind and 4.14 million had moderate-to-severe vision impairment because of glaucoma in 2020. () A study published online in June 2026 using Global Burden of Disease 2021 data found that the absolute number of modelled glaucoma cases increased by approximately 86% between 1990 and 2021, even though age-standardised prevalence and disability-adjusted life-year rates declined. Population growth and ageing explain much of this apparent contradiction: the risk at a given age may be falling, but more people are reaching the ages when glaucoma becomes common. () Regional disparities are marked Sub-Saharan Africa: high disease burden and late presentation Sub-Saharan Africa continues to experience the highest age-standardised burden of glaucoma-related blindness and moderate-to-severe vision impairment. In the 2020 global analysis, the age-standardised prevalence of glaucoma-related blindness among people aged 50 years and older was approximately 0.66% in Sub-Saharan Africa, compared with 0.20% globally. The region also had the highest age-standardised prevalence of glaucoma-related moderate-to-severe vision impairment. () A 2025 systematic review and Bayesian meta-analysis estimated glaucoma prevalence in Africa at 5.59%, with primary open-angle glaucoma accounting for approximately 5.07%. The pooled prevalence was highest in Southern Africa and lowest in East Africa, although the authors noted substantial variation between countries and studies. () Nigeria illustrates the scale of the problem. A national population survey estimated glaucoma prevalence at approximately 5.02% among people aged 40 years and older. In clinical and outreach settings, many people present after substantial damage has already occurred. These findings should not be interpreted as evidence that every Nigerian patient is diagnosed late, but they demonstrate the consequences of limited case detection and weak access to continuing care. () The problem is intensified by workforce distribution. A review of glaucoma needs among people of African descent reported that most ophthalmologists in Africa work in urban centres while much of the population lives in rural areas. It also cited estimates that approximately 90% of people with glaucoma in Africa may be unaware that they have the disease, although this figure comes from older and heterogeneous sources and should be interpreted cautiously. () Asia: large absolute numbers and angle-closure risk Asia contains a large share of the global population and therefore carries a substantial absolute glaucoma burden even where prevalence rates are lower than those reported in parts of Africa. The pattern of glaucoma also differs. Primary angle-closure glaucoma is more common in many East and Southeast Asian populations than in people of European ancestry. It can cause rapid and severe visual loss, particularly when an acute pressure crisis occurs. Primary open-angle glaucoma remains important throughout Asia, especially as populations age. () In younger regions of South and Southeast Asia, glaucoma may represent a smaller proportion of all blindness because cataract and other conditions remain more common. This does not mean the glaucoma burden is small. As life expectancy rises, the number of people needing long-term glaucoma monitoring is expected to increase. Europe and North America: better access, but underdiagnosis remains common High-income health systems generally have more ophthalmologists, diagnostic equipment, medicines, and insurance coverage. Yet they have not eliminated the detection gap. A 2025 analysis of 55,415 participants from seven European countries estimated glaucoma prevalence at 2.99% among adults aged 40 years and older. More than half of cases, 56.4%, had not previously been diagnosed. In people younger than 50 years, the proportion of undiagnosed disease exceeded 80%. Applying these estimates to the European population produced an estimate of 12.26 million people with glaucoma in 2024, including 6.86 million who were undiagnosed. () High-income countries had the highest proportion of blindness attributed to glaucoma in the 2020 global analysis—approximately 26%. This does not mean that high-income countries had the highest glaucoma blindness rate. Rather, cataract and other treatable causes of blindness are more often managed, leaving glaucoma as a larger share of the remaining blindness burden. () The Caribbean and African-descended populations People of African descent, including African-Caribbean populations, have a higher risk of primary open-angle glaucoma and may develop it at younger ages. The disease may also progress more aggressively in some patients. Barbados and several other Caribbean countries have reported a particularly high contribution of glaucoma to blindness. () These risks interact with social conditions. High medicine prices, missed appointments, limited surgical capacity, and mistrust after poor surgical experiences can produce severe disease even where specialist services technically exist. Why people are missed or untreated Glaucoma is usually asymptomatic early Early glaucoma often causes no pain and does not noticeably reduce central vision. People may continue reading, working, and driving while peripheral vision is gradually lost. This makes glaucoma different from conditions that encourage people to seek care quickly. A person may not feel an immediate benefit from eye drops, while side effects, inconvenience, and cost occur every day. This is one reason why diagnosis alone is not enough: patients must be able to start, continue, and monitor treatment. For this reason, the most practical approach is usually targeted case-finding followed by confirmatory assessment, rather than referring every person with one abnormal screening measurement directly into lifelong treatment. National Institute for Health and Care Excellence guidance describes a two-stage assessment in which an initial abnormal result is confirmed through a more detailed examination. () Affordability affects every stage of care The cost of glaucoma care includes more than the price of an eye drop. Patients may need to pay for: Transport to a clinic Several diagnostic tests Repeated visits Medicines for the rest of their lives Time away from work or caregiving Surgery and postoperative reviews Travel to a distant referral hospital A worldwide comparison of glaucoma treatment prices found that affordability varied greatly by country and household income. Timolol was generally the least expensive medicine, but the overall cost of treatment, laser, and surgery could still be substantial relative to household income in lower-income countries. () A 2024 Ghanaian cost-of-illness study found an average patient cost of approximately 60.78 United States dollars for glaucoma management. Direct costs accounted for about 94% of the total, with medicines responsible for 42% and laboratory or diagnostic services for 26%. Some patients paid out of pocket for timolol even though they expected it to be covered by the national insurance system. () These findings support a shift from isolated fee waivers to broader financial protection: essential medicines, diagnostic testing, transport support, and surgery all need to be considered. Adherence is a health-system issue, not simply a patient issue Common barriers to using glaucoma medicines include: Forgetting doses Difficulty putting drops into the eye Poor vision or arthritis that makes bottle handling difficult Complex schedules involving several medicines Eye irritation and other side effects Lack of understanding about an asymptomatic disease Medicine shortages Long travel distances to pharmacies or clinics Cost and insurance restrictionsSupport the show